Tevogen Bio Reports $5.4 Million Net Loss, Focuses on Immunotherapy Development

Tevogen Bio Holdings Inc. reported a net loss of $5.4 million for the three months ended March 31, 2026, a significant decrease from the $10.4 million loss recorded during the same period in 2025. The company's total operating expenses also fell to $5.4 million, down from $10.4 million year-over-year. This reduction was primarily driven by a decrease in general and administrative expenses, which dropped to $2.3 million from $7.2 million, largely due to lower legal and professional fees and a decrease in non-cash stock-based compensation. Research and development expenses remained relatively stable, totaling $3.1 million compared to $3.2 million in the prior year.

In terms of financial position, Tevogen's total assets increased to $4.9 million as of March 31, 2026, up from $4.4 million at the end of 2025. Current assets rose to $2.1 million, driven by an increase in cash and prepaid expenses. However, total liabilities also increased to $14.8 million, up from $12.6 million, primarily due to a rise in accounts payable and the outstanding balance on a loan agreement. The company’s stockholders’ deficit widened to $9.8 million from $8.2 million, reflecting ongoing operational losses.

Strategically, Tevogen Bio has been focused on advancing its clinical-stage immunotherapy products, particularly its lead candidate, TVGN 489, which is designed for treating high-risk COVID-19 patients. The company has completed a Phase 1 proof-of-concept trial for this product, with plans for further development. Additionally, Tevogen is leveraging artificial intelligence through its Tevogen.AI initiative to enhance drug development processes. The company also executed a reverse stock split in March 2026, aimed at improving its stock price and market perception.

Operationally, Tevogen has not yet generated revenue and continues to rely on external funding sources, including a loan agreement that allows for up to $36 million in financing. As of March 31, 2026, the company had $0.7 million in cash, which, along with anticipated proceeds from stock sales and grants, is expected to sustain operations for at least the next 12 months. The company is actively exploring additional funding strategies, including potential partnerships and public offerings, to support its ongoing research and development efforts.